Results 21 to 30 of about 264,861 (313)

SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA DEVELOPED AFTER TREATMENT OF NON-HODGKIN'S LYMPHOMA. CLINICAL CASE AND REVIEW OF LITERATURE.

Arta Medica, 2020
Background: Acute promyelocytic leukemia is an acute myeloid leukemia that accounts approximately 10% of acute myeloid leukemia cases. Acute promyelocytic leukemias usually appears as a de novo finding.
Victor Tomacinschii, Maria Robu, Vasile Musteață, Irina Mocanu, Sanda Buruiană, Natalia Sporîș, Veronica Feghiu   +6 more
doaj   +1 more source

Products of Vitamin D3 or 7-Dehydrocholesterol Metabolism by Cytochrome P450scc Show Anti-Leukemia Effects, Having Low or Absent Calcemic Activity [PDF]

, 2010
BACKGROUND. Cytochrome P450scc metabolizes vitamin D3 to 20-hydroxyvitamin D3 (20(OH)D3) and 20,23(OH)2D3, as well as 1-hydroxyvitamin D3 to 1a,20-dihydroxyvitamin D3 (1,20(OH)2D3).
Chen, Tai C., Fuller, Brian E., Holick, Michael F., Janjetovic, Zorica, Li, Wei, Lozanski, Gerard, Miller, Duane, Nguyen, Minh N., Slominski, Andrzej T., Sweatman, Trevor, Tuckey, Robert C., Zjawiony, Jordan, Zmijewski, Michal A.   +12 more
core   +8 more sources

Molecular methods for genomic analyses of variant PML-RARA or other RARA-related chromosomal translocations in acute promyelocytic leukemia [PDF]

, 2012
TO THE EDITOR: We read an interesting paper by Palta et al. in a recent issue of the Korean Journal of Hematology titled, "ZBTB16-RARA variant of acute promyelocytic leukemia with tuberculosis: a case report and review of literature" [1].
Kim, Min Jin, Marschalek, Rolf, Meyer, Claus, Park, Tae Sung, Yang, John Jeongseok   +4 more
core   +1 more source

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

New England Journal of Medicine, 2013
BACKGROUND All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%.
F. Lo‐Coco, G. Avvisati, M. Vignetti, C. Thiede, S. Orlando, S. Iacobelli, F. Ferrara, P. Fazi, L. Cicconi, E. di Bona, G. Specchia, S. Sica, M. Divona, A. Levis, W. Fiedler, E. Cerqui, M. Breccia, G. Fioritoni, H. Salih, M. Cazzola, L. Melillo, A. Carella, C. Brandts, E. Morra, M. von Lilienfeld-Toal, B. Hertenstein, M. Wattad, M. Lübbert, M. Hänel, N. Schmitz, H. Link, M. Kropp, A. Rambaldi, G. La Nasa, M. Luppi, F. Ciceri, O. Finizio, A. Venditti, F. Fabbiano, K. Döhner, M. Sauer, A. Ganser, S. Amadori, F. Mandelli, H. Döhner, G. Ehninger, R. Schlenk, U. Platzbecker   +47 more
semanticscholar   +1 more source

Frontline ATRA ‐ ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG ‐ APL2017 Trial

Cancer Science, EarlyView.
FBMTG‐APL2017: First prospective multicenter trial evaluating frontline ATRA‐ATO therapy for newly diagnosed APL in Japan, encompassing both low–intermediate (n = 65) and high‐risk (n = 16) patients. Excellent outcomes (95% CR, 94% 3‐year DFS) with comparable efficacy between risk groups (DFS: 97% vs.
Ken Takase, Tomohiko Kamimura, Takuro Kuriyama, Takahito Tokuyama, Hideho Henzan, Yoshikane Kikushige, Ilseung Choi, Yutaka Imamura, Akio Mori, Shuki Ohya, Noriaki Kawano, koji Yonemoto, Mine Harada, Koichi Akashi, T. Miyamoto   +14 more
openalex   +2 more sources

The CEBPA gene is down-regulated in acute promyelocytic leukemia and its upstream promoter, but not the core promoter, is highly methylated

Haematologica, 2011
Impairment of CCAAT Enhancer Binding Protein alpha (CEBPA) function is a common finding in acute myeloid leukemia; nevertheless, its relevance for acute promyelocytic leukemia pathogenesis is unclear.
Bárbara Amélia Santana-Lemos, Ana Paula Alencar de Lima Lange, Mariana Tereza de Lira Benício, Thiago Donizete da Silva José, Antônio Roberto Lucena-Araújo, Alexandre Krause, Carolina Hassibe Thomé, Eduardo Magalhães Rego   +7 more
doaj   +1 more source

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.

Blood, 2019
Since the comprehensive recommendations for the management of acute promyelocytic leukemia (APL) reported in 2009, several studies have provided important insights, particularly regarding the role of arsenic trioxide (ATO) in frontline therapy. Ten years
M. Sanz, P. Fenaux, M. Tallman, E. Estey, B. Löwenberg, T. Naoe, E. Lengfelder, H. Döhner, A. Burnett, Saijuan Chen, V. Mathews, H. Iland, E. Rego, H. Kantarjian, L. Adès, G. Avvisati, P. Montesinos, U. Platzbecker, F. Ravandi, N. Russell, F. Lo‐Coco   +20 more
semanticscholar   +1 more source

Severe acute axonal neuropathy following treatment with arsenic trioxide for acute promyelocytic leukemia: a case report [PDF]

, 2016
Peripheral neuropathy is a common complication of arsenic toxicity. Symptoms are usually mild and reversible following discontinuation of treatment. A more severe chronic sensorimotor polyneuropathy characterized by distal axonal-loss neuropathy can be ...
Kuhn, Marcus, Nabergoj, Mithia, Sammartin, Kety, Vianello, Fabrizio   +3 more
core   +3 more sources

A case of acute myeloid leukemia with promyelocytic features characterized by expression of a novel RARG-CPSF6 fusion [PDF]

, 2018
Key Points Novel RARG-CPSF6 fusion in an AML case with promyelocytic features and no evidence of PML-RARA or X-RARA fusion. Gene fusions involving RARG can initiate AML with promyelocytic morphological features.
Duncavage, Eric J., Griffith, Malachi, Griffith, Obi L., Hassan, Anjum, Lee, Yi-Shan, Miller, Christopher A., O\u27Laughlin, Michelle D., Schmidt, Heather, Skidmore, Zachary L., Tian, Ling, Tricarico, Christopher, Uy, Geoffrey L., Wartman, Lukas D., Welch, John S.   +13 more
core   +2 more sources

Advances in Pediatric Acute Promyelocytic Leukemia

Children, 2020
Acute promyelocytic leukemia (APL) is a rare disease accounting for only 5%–10% of pediatric acute myeloid leukemia (AML) and fewer than 1000 cases occur annually in the United States across all age groups.
Shannon E. Conneely, A. Stevens
semanticscholar   +1 more source